Expiring Soon! On-Demand CE on SGLT-2 Inhibitors

The Whole New World of SGLT-2 Inhibitors: Looking into the Cardio-Kidney-Metabolic Space

This educational activity will provide an overview of CKM syndrome and evidence supporting early screening and treatment. The latest data from all landmark clinical trials, systematic reviews, and meta-analyses demonstrating the benefit of SGLT2 inhibitors on cardiorenal outcomes and clinical trials currently underway to identify potential emerging areas for SGLT2 inhibitor benefit will be presented. A review of the latest clinical practice guidelines for the use of SGLT2 inhibitors in heart failure, kidney disease, and diabetes will be shared. The activity will conclude with an exploration of interprofessional care models that address barriers and incorporate pharmacists into the initiation, titration, and monitoring of SGLT2 inhibitor therapy for patients who could benefit from treatment.

 We invite you to share this free educational activity with your colleagues. 

Featuring...

 Leo F. Buckley

PharmD, MPH, BCCP
Activity Chair

 Clinical Pharmacy Specialist
Brigham and Women’s Hospital
Boston, Massachusetts

  Susan Cornell  

PharmD, CDCES, FAPhA, FADCES

 Director of Experiential Education, Professor in Pharmacy Practice – Midwestern University College of Pharmacy, Downers Grove, IL
Diabetes Care & Education Specialist – Bolingbrook Christian Health Center
Bolingbrook, Illinois

Target Audience

This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, community pharmacies, and ambulatory clinics who care for or are interested in the care of patients who have type 2 diabetes, heart failure, and/or chronic kidney disease.

Learning Objectives

• Identify people who have T2D, HF, and/or CKD who would benefit from early initiation of SGLT2 inhibitor therapy.
• Formulate an evidence-based treatment plan to reduce cardiorenal risk in people with cardio-renal-metabolic comorbidities based on current clinical practice guidelines and person-specific factors. 
• Apply best practices from interprofessional care models that support the implementation of cardio-renal-metabolic therapies in different practice settings. 

Agenda

Welcome and Introductions
Leo F. Buckley
 

The Heart of it All: Identifying People Who May Benefit from SGLT2 Inhibitor Treatment 

Leo F. Buckley
 

Filtering the Evidence: Designing Individualized SGLT2 Inhibitor Treatment Plans for People with T2D, HF, and/or CKD Based on Guidelines and Evidence-Based Practices 

Susan Cornell
 

Putting It into Practice (Case-based Examples): Interprofessional Care Models for the Initiation and Optimization of Therapy in People with T2D, HF, and/or CKD 

All Faculty
 

Faculty Discussion, Questions and Answers

All Faculty

Accredited for CPE

ACPE #: 0204-0000-24-406-H01-P

CE Credit: 1.5 contact hours (0.15 CEUs)

Activity Type: Application-based

Activity Fee: No charge 

Available: February 13, 2025 - February 13, 2026

To receive CE credit, complete the steps below within 60 days of completing the activity.

1. View entire presentation and answer all polling questions.
2. Click "Complete Activity" on the last slide to complete the assessment and evaluation.
3. Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.

After the 60-day deadline, ASHP will no longer be able to report credits(s).